A Multicenter, Prospective, Single Arm, Open Label, Post-Market, Observational Study to evaluate the use of sTMS in reduction of Migraine Headache (ESPOUSE Study) (S52.004)

Conclusions:This open label study suggests that sTMS may be an effective, well-tolerated treatment option for migraine prevention.Study Supported by:The ESPOUSE Study was supported by eNeura Inc.Disclosure: Dr. Starling has received personal compensation for activities with Amgen and eNeura as a consultant. Dr. Tepper has received personal compensation for activities with Acorda, Alder, Allergan, Amgen, ATI, Avanir, Dr. Reddy's, eNeura, Pfizer, Scion Neurostim, Teva, Zosana, Depomed, Impax, Pernix, Teva, Amgen, and Merck. Dr. Tepper has received personal compensation in an editorial capacity for Headache Currents. Dr. Tepper holds stock and/or stock options in ATI. Dr. Tepper has received research support from Alder, Allergan, Amgen, ATI, Scion Neurostim, Teva, Zosano. Dr. Marmura has received personsal compensation for activities with Teva and Supernus as a consultant. Dr. Marmura has received research support for Teva and eNeura. Dr. Shamim has nothing to disclose. Dr. Robbins has received personal compensation in an editorial capacity for Current Pain and Headache Reports. Dr. Robbins has received research support from eNeura. Dr. Hindiyeh has nothing to disclose. Dr. Charles has received personal compensation for activities with Amgen as a consultant and with eNeura and Eli Lilly for serving on the Scientific Advisory Board. Dr. Charles has received research support from Takeda. Dr. Goadsby has received personal compensation for activities with Allergan, eNeura, Autonomic...

Source: Neurology - April 17, 2017 Category: Neurology Authors: Starling, A. J., Tepper, S., Marmura, M. J., Shamim, E. A., Robbins, M., Hindiyeh, N., Charles, A. C., Goadsby, P. J., Lipton, R. B., Silberstein, S. D., Dodick, D. W. Tags: Headache: Clinical Trials and Disease Burden Source Type: research